美国Athersys  
Athersys公司是一家生物制药公司，旨在从事开发为提高人类生活质量的产品。公司的产品组合包括干细胞产品MultiStem，这正在发展成为多种疾病的适应症治疗，并正在评估两个进行中的临床试验，并一直在第三临床试验授权使用。此外，该公司正在开发药品来治疗如肥胖、某些认知和注意力障碍和嗜睡症或其他形式的白天过度嗜睡的疾病。公司成立于1995年，总部位于美国.

We are a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. Through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple disease areas. We are committed to developing therapeutic products that we believe have best-in-class potential, meaning therapeutic candidates that have the potential to be safer and more effective products than the current standard of care or other products in development, and that may have other advantages, such as superior scalability or ease of administration. Our lead product development programs utilize MultiStem®, a proprietary stem cell product that we believe could be beneficial in the treatment for multiple disease indications in the cardiovascular, neurological, and inflammatory and immune disease areas, as well as certain other conditions. MultiStem is currently being evaluated in several clinical stage programs, as well as a range of preclinical programs. In addition, we are developing novel pharmaceuticals to treat indications such as obesity and related metabolic conditions, as well as certain neurological disorders.

Athersys was established in October, 1995, and since 2007 has been a publicly listed company on the NASDAQ exchange (Ticker: ATHX). The company has operations in Cleveland, Ohio and Leuven, Belgium.

We work collaboratively with leading investigators from clinical and research institutions around the world. In recent years, we have worked with over investigators from over 30 leading institutions across the United States and Europe. In addition, we work with leading pharmaceutical and biotechnology companies to accelerate development of our technologies and products. We are committed to scientific excellence, patient safety, and to developing safer and more effective new therapies that can address significant unmet medical needs, and enhance the lives of patients that need help. We believe that this commitment will enable us to create substantial value for our shareholders.